| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | General Counsel | Employee Stock Option (right to buy) | 500,000 | 23 Feb 2023 | Direct | ||
| ArriVent BioPharma, Inc. | General Counsel | Stock Option (right to buy) | 130,000 | 02 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AVBP | ArriVent BioPharma, Inc. | 02 Feb 2026 | 1 | $0 | 4 | General Counsel | 04 Feb 2026, 20:39 |
| AVBP | ArriVent BioPharma, Inc. | 03 Feb 2025 | 1 | $0 | 4 | General Counsel | 14 Feb 2025, 16:23 |
| AVBP | ArriVent Biopharma, Inc. | 25 Jan 2024 | 0 | $0 | 3 | General Counsel | 25 Jan 2024, 20:38 |
| SYRE | Aeglea BioTherapeutics, Inc. | 23 Feb 2023 | 1 | $0 | 4 | General Counsel | 24 Feb 2023, 17:24 |
| SYRE | Aeglea BioTherapeutics, Inc. | 23 Aug 2022 | 1 | $0 | 4 | Interim CEO & General Counsel | 25 Aug 2022, 19:39 |
| SYRE | Aeglea BioTherapeutics, Inc. | 23 Aug 2022 | 0 | $0 | 3 | Interim CEO & General Counsel | 25 Aug 2022, 19:37 |